The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures

Postpartum Hemorrhage Clinical Trial

Official title:

The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures: A Multi-Site Longitudinal Study An Initiative Under the East African Women's Health Network (EAWoHNet)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01844089
• Other study ID #: Pro00029944
• Status: Completed
• Phase: N/A
• First received: April 29, 2013
• Last updated: February 12, 2015
• Start date: October 2013
• Est. completion date: January 2015

Study information

• Verified date: February 2015
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review BoardKenya: IREC and GERC
• Study type: Observational

Clinical Trial Summary

The broad objective of the study is to determine if the Bakri Postpartum Balloon is effective in preventing morbidity and mortality from postpartum hemorrhage (PPH) as part of a standardized management algorithm.

Specific Objectives

• To estimate the rate of morbidity (including operative intervention and peripartum hysterectomy) and mortality secondary to PPH in 4 academic centers after introduction of a standardized protocol for management of PPH, but prior to the inclusion of the Bakri Postpartum Balloon as part of the protocol.

• To estimate the rate of morbidity (including operative intervention and peripartum hysterectomy) and mortality secondary to PPH in 4 academic centers after introduction of a standardized protocol for management of PPH, after the inclusion of the Bakri Postpartum Balloon as part of the protocol.

• To compare morbidity

• To generate preliminary data for (a) a larger confirmatory study of the use of the Bakri Postpartum Balloon in centers with surgical and blood transfusion services, and (b) design of a pilot study of the use of the Bakri device of temporary control of PPH in settings outside of surgical centers (such as by trained midwives or emergency transport personnel).

Description:

Phase I: Development and training of staff in standardized algorithm for management of PPH using available local resources (not including Bakri balloon).

Phase II: Data collection after introduction of the standardized algorithm.

Phase III: Revision of protocol to include the Bakri Postpartum Device

Phase IV: Data collection after introduction of the Bakri device

Bakri Postpartum Balloon 510K Premarket Notification/Cook OBGYN #K062438

Recruitment information / eligibility

• Status: Completed
• Enrollment: 57
• Est. completion date: January 2015
• Est. primary completion date: January 2015
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any woman who recently delivered by either vaginal or cesarean delivery who experiences postpartum hemorrhage, defined as

• Clinically estimated blood loss of greater than 500 ml for a vaginal delivery, or

• Clinically estimated blood loss of greater than 1000 ml for a cesarean delivery, or

• Hemodynamic changes that, in the opinion of the care team, require interventions beyond routine postpartum or postdelivery care (such as intravenous fluids or the use of more than one uterotonic agent).

Exclusion Criteria:

• Minors (less than 18 years of age)

• Arterial bleeding requiring surgical exploration or angiographic embolization

• Cases requiring immediate lifesaving hysterectomy

• Ongoing intrauterine pregnancy

• Cervical cancer

• Purulent infections of the vagina, cervix or uterus

• Untreated uterine anomaly

• Disseminated intravascular coagulation

• A surgical site which would prohibit the device from effectively controlling bleeding

• Patients who are referred for obstructed labor

• Patients with signs, symptoms or other evidence of ruptured uterus

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Hemorrhage
• Postpartum Hemorrhage

Locations

Country	Name	City	State
Kenya	MOI Teaching and Referral Hospital	Eldoret
Kenya	Great Lakes University	Kisumu

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Cook

Country where clinical trial is conducted

Kenya, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of women with febrile morbidity	febrile morbidity and individual rates of the components of the composite primary outcome	24 hours	No
Primary	Composite clinical outcome	The primary outcome of the study is a composite clinical outcome consisting of: Blood transfusion; Renal failure (creatinine >1.5 mg/dL or increased >1.0 mg/dL above baseline, oliguria <120 ml output in 4 hour intervals); Respiratory impairment (impairment of respiratory function requiring ventilation, oxygen supplementation, or decreased physical activity compared to pre-pregnancy levels); Central nervous system impairment (seizures, loss of consciousness, or cognitive/motor loss); Heart failure (NYHA class III or IV); Disseminated intravascular coagulation (DIC) based on clinical and laboratory assessment if available.; Abdominal surgery to control hemorrhage in non-cesarean patients; Emergency hysterectomy. Outcomes and definitions are similar to those used in other studies of PPH management in Africa.	24 hours	No
Secondary	Unit of estimated blood loss	Mean and median estimated blood loss	24 hours	No